Renal hemangiopericytoma secondary to refractory hypertension in a child: A case report

por HU, QINGFENG, FANG, ZUJUN, ZHOU, ZHONGWEN, ZHENG, JIE
Publicado 2014

Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation

por Hui, Wen, Liu, Shenghua, Zheng, Jie, Fang, Zujun, Ding, Qiang, Feng, Chenchen
Publicado 2018

Comparison of the characteristics of mesenchymal stem cells obtained from prostate tumors and from bone marrow cultured in conditioned medium

por DING, GUANXIONG, SHAO, JIALIANG, DING, QIANG, FANG, ZUJUN, WU, ZHONG, XU, JIANFENG, GAO, PENG
Publicado 2012

EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression

por Li, Shibao, Ma, Yingyu, Xie, Chongwei, Wu, Zhiyuan, Kang, Zhihua, Fang, Zujun, Su, Bing, Guan, Ming
Publicado 2015

The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer

por Chen, Zhongqing, Ding, Weihong, Xu, Ke, Tan, Jun, Sun, Chuanyu, Gou, Yuancheng, Tong, Shijun, Xia, Guowei, Fang, Zujun, Ding, Qiang
Publicado 2012

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent

por Xiong, Zuquan, Zang, Yiwen, Zhong, Shan, Zou, Lujia, Wu, Yishuo, Liu, Shenghua, Fang, Zujun, Shen, Zhoujun, Ding, Qiang, Chen, Shanwen
Publicado 2017

RNA Sequencing Reveals Upregulation of RUNX1-RUNX1T1 Gene Signatures in Clear Cell Renal Cell Carcinoma

por Xiong, Zuquan, Yu, Hongjie, Ding, Yan, Feng, Chenchen, Wei, Hanming, Tao, Sha, Huang, Dan, Zheng, Siqun Lilly, Sun, Jielin, Xu, Jianfeng, Fang, Zujun
Publicado 2014

Genetic risk scores based on risk-associated single nucleotide polymorphisms can reveal inherited risk of bladder cancer in Chinese population

por Xu, Chenyang, Lin, Xiaoling, Qian, Wei, Na, Rong, Yu, Hongjie, Jia, Haifei, Jiang, Haowen, Fang, Zujun, Zheng, S. Lilly, Ding, Qiang, Wu, Yishuo, Zheng, Jie, Xu, Jianfeng
Publicado 2020

A Germline Variant at 8q24 Contributes to the Serum p2PSA Level in a Chinese Prostate Biopsy Cohort

por Lin, Xiaoling, Wu, Yishuo, Liu, Fang, Na, Rong, Huang, Da, Xu, Danfeng, Gong, Jian, Zhu, Yao, Dai, Bo, Ye, Dingwei, Yu, Hongjie, Jiang, Haowen, Fang, Zujun, Zheng, Jie, Ding, Qiang
Publicado 2021

Hengli(®) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

por Liao, Limin, Liu, Qinggang, Cong, Huiling, Xu, Zhihui, Li, Enhui, Weng, Zhiliang, Jiang, Haihong, Liu, Ben, Huang, Xiao, Xia, Shujie, Wen, Wei, Wu, Juan, Shi, Guowei, Wang, Yang, Li, Peijun, Yu, Yang, Fang, Zujun, Zheng, Jie, Tian, Ye, Shang, Donghao, Li, Hanzhong, Huang, Zhongming, Zhou, Liqun, Xiao, Yunxiang, Zhang, Yaoguang, Wang, Jianlong, Zhang, Xiaodong, Zhang, Peng, Wang, Dongwen, Zhang, Xuhui, Xie, Keji, Wang, Bin, Ma, Lulin, Tian, Xiaojun, Chen, Lijun, Dong, Jinkai
Publicado 2022